JP2018534311A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018534311A5 JP2018534311A5 JP2018525700A JP2018525700A JP2018534311A5 JP 2018534311 A5 JP2018534311 A5 JP 2018534311A5 JP 2018525700 A JP2018525700 A JP 2018525700A JP 2018525700 A JP2018525700 A JP 2018525700A JP 2018534311 A5 JP2018534311 A5 JP 2018534311A5
- Authority
- JP
- Japan
- Prior art keywords
- dose
- raf
- inhibitor
- administered
- medicament according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 38
- 102000018471 Proto-Oncogene Proteins B-raf Human genes 0.000 claims 28
- 108010091528 Proto-Oncogene Proteins B-raf Proteins 0.000 claims 28
- 239000003112 inhibitor Substances 0.000 claims 23
- 201000001441 melanoma Diseases 0.000 claims 15
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 10
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 10
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 10
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 10
- 229940124647 MEK inhibitor Drugs 0.000 claims 7
- 229960002271 cobimetinib Drugs 0.000 claims 7
- RESIMIUSNACMNW-BXRWSSRYSA-N cobimetinib fumarate Chemical group OC(=O)\C=C\C(O)=O.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F RESIMIUSNACMNW-BXRWSSRYSA-N 0.000 claims 7
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims 7
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical group CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 claims 5
- 229960003862 vemurafenib Drugs 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 229960003852 atezolizumab Drugs 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- -1 (S)-[3,4-difluoro-2- (2-fluoro-4-iodophenylamino) phenyl] [3-hydroxy-3- (piperidin-2-yl) azetidin-1-yl ] Chemical group 0.000 claims 2
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 208000021039 metastatic melanoma Diseases 0.000 claims 2
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 230000005723 MEK inhibition Effects 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 238000011275 oncology therapy Methods 0.000 claims 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical group CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562257645P | 2015-11-19 | 2015-11-19 | |
| US62/257,645 | 2015-11-19 | ||
| PCT/US2016/062859 WO2017087851A1 (en) | 2015-11-19 | 2016-11-18 | Methods of treating cancer using b-raf inhibitors and immune checkpoint inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018534311A JP2018534311A (ja) | 2018-11-22 |
| JP2018534311A5 true JP2018534311A5 (enExample) | 2019-12-26 |
| JP6952691B2 JP6952691B2 (ja) | 2021-10-20 |
Family
ID=57485956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018525700A Active JP6952691B2 (ja) | 2015-11-19 | 2016-11-18 | Ｂ−ｒａｆ阻害剤及び免疫チェックポイント阻害剤を使用してがんを治療する方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20180256552A1 (enExample) |
| EP (1) | EP3377107B1 (enExample) |
| JP (1) | JP6952691B2 (enExample) |
| KR (1) | KR102702851B1 (enExample) |
| CN (2) | CN121154828A (enExample) |
| AU (1) | AU2016355320B2 (enExample) |
| ES (1) | ES2824120T3 (enExample) |
| HK (1) | HK1256367A1 (enExample) |
| IL (1) | IL259055B (enExample) |
| MX (1) | MX377351B (enExample) |
| PL (1) | PL3377107T3 (enExample) |
| WO (1) | WO2017087851A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2978942A1 (en) | 2015-03-13 | 2016-09-22 | Cytomx Therapeutics, Inc. | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof |
| EP3932428A1 (en) | 2015-05-21 | 2022-01-05 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
| AU2017205089B2 (en) | 2016-01-08 | 2023-10-05 | F. Hoffmann-La Roche Ag | Methods of treating CEA-positive cancers using PD-1 axis binding antagonists and anti-CEA/anti-CD3 bispecific antibodies |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| JP7300394B2 (ja) | 2017-01-17 | 2023-06-29 | ヘパリジェニックス ゲーエムベーハー | 肝再生の促進又は肝細胞死の低減もしくは予防のためのプロテインキナーゼ阻害 |
| KR20200016899A (ko) * | 2017-06-01 | 2020-02-17 | 싸이톰스 테라퓨틱스, 인크. | 활성화가능 항-pdl1 항체, 및 이의 이용 방법 |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| CN111630070B (zh) | 2017-10-13 | 2024-07-30 | 哈普恩治疗公司 | 三特异性蛋白质及使用方法 |
| WO2020061482A1 (en) | 2018-09-21 | 2020-03-26 | Harpoon Therapeutics, Inc. | Egfr binding proteins and methods of use |
| US10815311B2 (en) | 2018-09-25 | 2020-10-27 | Harpoon Therapeutics, Inc. | DLL3 binding proteins and methods of use |
| US20210348238A1 (en) * | 2018-10-16 | 2021-11-11 | Novartis Ag | Tumor mutation burden alone or in combination with immune markers as biomarkers for predicting response to targeted therapy |
| WO2021016228A1 (en) * | 2019-07-22 | 2021-01-28 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Combination therapy for treating ras-mutant cancers |
| WO2022131667A1 (ko) * | 2020-12-18 | 2022-06-23 | 경희대학교 산학협력단 | Oligodendrocyte transcription factor 2 억제제를 유효성분으로 포함하는 흑색종 치료 효과 증진용 약학적 조성물 |
| CN117202897A (zh) * | 2021-04-09 | 2023-12-08 | 基因泰克公司 | 使用raf抑制剂和pd-1轴抑制剂的组合疗法 |
| WO2024102954A1 (en) | 2022-11-10 | 2024-05-16 | Massachusetts Institute Of Technology | Activation induced clipping system (aics) |
| WO2025059162A1 (en) | 2023-09-11 | 2025-03-20 | Dana-Farber Cancer Institute, Inc. | Car-engager containing il-2 variants to enhance the functionality of car t cells |
| WO2025235862A1 (en) | 2024-05-10 | 2025-11-13 | Inndura Therapeutics Inc. | A modified immune cell receptor comprising a target-binding domain and the extracellular domain of cd16a |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| TW200639163A (en) | 2005-02-04 | 2006-11-16 | Genentech Inc | RAF inhibitor compounds and methods |
| DK2161336T4 (en) | 2005-05-09 | 2017-04-24 | Ono Pharmaceutical Co | Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies |
| TWI473808B (zh) | 2005-06-22 | 2015-02-21 | Plexxikon Inc | 用於激酶調節的化合物及方法及其適應症 |
| RS54271B1 (sr) | 2005-07-01 | 2016-02-29 | E. R. Squibb & Sons, L.L.C. | Humana monoklonska antitela za ligand programirane smrti 1 (pd-l1) |
| ATE504565T1 (de) | 2005-10-07 | 2011-04-15 | Exelixis Inc | Azetidine als mek-inhibitoren bei der behandlung proliferativer erkrankungen |
| MX2010008786A (es) | 2008-02-11 | 2010-12-01 | Curetech Ltd | Anticuerpos monoclonales para tratamiento de tumores. |
| CA2716947A1 (en) | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | Imidazo [4,5-b] pyridine derivatives used as raf inhibitors |
| CA2716949A1 (en) | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer |
| US8394795B2 (en) | 2008-02-29 | 2013-03-12 | Array Biopharma Inc. | Pyrazole [3, 4-B] pyridine Raf inhibitors |
| WO2009111278A2 (en) | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| CN102203125A (zh) | 2008-08-25 | 2011-09-28 | 安普利穆尼股份有限公司 | Pd-1拮抗剂及其使用方法 |
| HRP20170908T1 (hr) | 2008-12-09 | 2017-09-22 | F. Hoffmann - La Roche Ag | Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice |
| PT2504364T (pt) | 2009-11-24 | 2017-11-14 | Medimmune Ltd | Agentes de ligação direcionados contra b7-h1 |
| JP2013512251A (ja) | 2009-11-24 | 2013-04-11 | アンプリミューン、インコーポレーテッド | Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害 |
| BR112015003418A2 (pt) * | 2012-08-17 | 2017-07-04 | Hoffmann La Roche | produto farmacêutico, conjunto, métodos para estender a duração da resposta ao tratamento, de retardar ou prevenir o desenvolvimento de resistência ao tratamento, para a seleção de uma terapia e para otimizar a eficácia terapêutica. |
| WO2014193898A1 (en) * | 2013-05-31 | 2014-12-04 | Merck Sharp & Dohme Corp. | Combination therapies for cancer |
| KR20160013049A (ko) * | 2013-06-03 | 2016-02-03 | 노파르티스 아게 | 항-pd-l1 항체 및 mek 억제제 및/또는 braf 억제제의 조합물 |
-
2016
- 2016-11-18 AU AU2016355320A patent/AU2016355320B2/en active Active
- 2016-11-18 ES ES16806416T patent/ES2824120T3/es active Active
- 2016-11-18 PL PL16806416T patent/PL3377107T3/pl unknown
- 2016-11-18 CN CN202510876831.3A patent/CN121154828A/zh active Pending
- 2016-11-18 JP JP2018525700A patent/JP6952691B2/ja active Active
- 2016-11-18 MX MX2018006152A patent/MX377351B/es active IP Right Grant
- 2016-11-18 EP EP16806416.0A patent/EP3377107B1/en active Active
- 2016-11-18 KR KR1020187016785A patent/KR102702851B1/ko active Active
- 2016-11-18 WO PCT/US2016/062859 patent/WO2017087851A1/en not_active Ceased
- 2016-11-18 HK HK18115456.5A patent/HK1256367A1/zh unknown
- 2016-11-18 CN CN201680051333.4A patent/CN108136022A/zh active Pending
-
2018
- 2018-04-30 IL IL259055A patent/IL259055B/en unknown
- 2018-05-18 US US15/984,067 patent/US20180256552A1/en not_active Abandoned
-
2019
- 2019-11-13 US US16/683,082 patent/US20200155520A1/en not_active Abandoned
-
2023
- 2023-12-18 US US18/544,236 patent/US20240115555A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018534311A5 (enExample) | ||
| CN102089007B (zh) | (a)磷酸肌醇3-激酶抑制剂和(b)ras/raf/mek通路调节剂的组合产品 | |
| JP7194022B2 (ja) | Ｎｏｔｃｈ阻害剤とＰＤ－１またはＰＤ－Ｌ１阻害剤との併用療法 | |
| JP2017529382A5 (enExample) | ||
| US20100160351A1 (en) | Pharmaceutical compositions and methods for treating hyperuricemia and related disorders | |
| JP2017502017A5 (enExample) | ||
| JP2017522307A5 (enExample) | ||
| DeMaagd et al. | Part 2: Introduction to the pharmacotherapy of Parkinson’s disease, with a focus on the use of dopaminergic agents | |
| JP2014509657A5 (enExample) | ||
| JP2009514874A5 (enExample) | ||
| JP2013539767A5 (enExample) | ||
| JP2019511526A5 (enExample) | ||
| JP2018507243A5 (enExample) | ||
| JP2018519324A5 (enExample) | ||
| JP2014532648A5 (enExample) | ||
| WO2018060463A3 (en) | Treatment of prostate cancer | |
| Pardanani et al. | A phase I/II study of CYT387, an oral JAK-1/2 inhibitor, in myelofibrosis: significant response rates in anemia, splenomegaly, and constitutional symptoms | |
| NO20073403L (no) | Anvendelse av atazanavir til forbedring av farmakokinetikken til legemidler metabolisert av UGT1A1 | |
| JP2018530578A5 (enExample) | ||
| JP2017502016A5 (enExample) | ||
| JP2021509395A5 (enExample) | ||
| JP2019526559A5 (enExample) | ||
| JP2015517523A5 (enExample) | ||
| Gibofsky et al. | Lower-dose diclofenac submicron particle capsules provide early and sustained acute patient pain relief in a phase 3 study | |
| US20130131069A1 (en) | Method for treatment of solid malignancies including advanced or metastatic solid malignancies |